PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of of anti-PD-1 antibody in
combination with chemotherapy as first-line treatment in patients with unresectable, locally
advanced recurrent or metastatic serum AFP-elevated gastric and gastroesophageal junction
adenocarcinoma.